Legend Biotech CEO Ying Huang Resigns After Seven Years
LEGN sits 32% above its 52-week low of $16.24.
Summary
CEO Ying Huang has stepped down after seven years at the helm. Alan Bash, president of the CARVYKTI business unit, takes over as interim CEO while the board searches for a permanent successor. Huang will stay on as an advisor through August to ensure a smooth transition. This is a sudden leadership change at a critical juncture — the company just reported strong CARVYKTI sales growth and promising early data for its next-generation CAR-T therapies. The departure raises questions about strategic continuity, especially with the recent $226M offering still fresh. The market will want clarity on the reasons behind the exit and the timeline for a permanent appointment.
At the time of this announcement, LEGN was trading at $21.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $16.24 to $44.78. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.